Does the number of previous vaginal deliveries affect overactive baldder symptoms and their response to treatment
| Autor: | Lambertus P. W. Witte, Martin C. Michel, Jean J.M.C.H. de la Rosette, Ursula Peschers, Monika Vogel |
|---|---|
| Přispěvatelé: | Urology, Cancer Center Amsterdam, Amsterdam Public Health, Other Research, Pharmacology and pharmacotherapeutics |
| Jazyk: | angličtina |
| Rok vydání: | 2009 |
| Předmět: |
medicine.medical_specialty
Solifenacin business.industry Vaginal delivery Urology Muscarinic antagonist urologic and male genital diseases medicine.disease Affect (psychology) Response to treatment female genital diseases and pregnancy complications Neurology Overactive bladder Rating scale Internal medicine medicine Observational study business medicine.drug |
| Zdroj: | LUTS : Lower urinary tract symptoms, 1(2), 82-87. Wiley Blackwell |
| ISSN: | 1757-5664 |
| DOI: | 10.1111/j.1757-5672.2009.00051.x |
| Popis: | Objectives: To explore associations between the number of vaginal deliveries (primary aim) or gender (secon- dary aim) and overactive bladder (OAB) symptoms as well as their response to treatment with a muscarinic antagonist. Methods: Preplanned secondary analysis of an observational study of solifenacin in OAB patients. Episode frequencies of OAB symptoms, pad use and scores on OAB rating scales were documented in 4450 patients before and after a 12–14 week treatment period with solifenacin 5 or 10 mg. Results: Women without, and with one, two or more than two vaginal deliveries and men were similar in their baseline characteristics. All groups also exhibited rather similar reductions in symptoms and improvements in rating scales upon treatment. Conclusion: These data indicate that solifenacin, and perhaps other muscarinic receptor antagonists, are similarly suitable for the treatment of OAB symptoms in both genders, irrespective of previous vaginal deliveries. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text